Home LiteratureArticle Details
PMID: 2159365 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.

Cancer research ·Vol. 50 ·No. 10 ·1990-05-15 ·Pages 2901-8

Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK

Abstract

The activity of topoisomerase II and the cellular content of the 170kD and 180kD forms of the enzyme were studied as functions of transformation and growth state by using normal and ras-transformed NIH-3T3 cells. Total topoisomerase II activity, as measured by the unknotting of P4 DNA, was higher in ras-transformed than in normal cells in similar growth states, and was higher in exponentially growing than in plateau cells for both cell lines. Total topoisomerase II levels, as measured by immunoblotting, showed a similar dependence on transformation and growth state. The relative amounts of the 170kD and 180kD forms of the enzyme varied as a function of transformation and growth state. The proportion of 170kD topoisomerase II was higher in ras-transformed than in untransformed cells and depended much less on growth state in the ras-transformed cells. The topoisomerase II activity in extracts of ras-transformed cells was more sensitive to inhibition by teniposide and merbarone, drugs which selectively inhibit the 170kD form of topoisomerase II. The ras-transformed cells were also more sensitive to the cytotoxic effects of these drugs. An increase in the relative cellular content of 170kD topoisomerase II is characteristic of ras-transformed 3T3 cells, and the levels of this form of the enzyme appear to be less dependent on proliferation state than in untransformed cells. The susceptibility of certain tumors to killing by topoisomerase II-directed drugs may be due to a higher proportion of 170kD enzyme as well as a higher level of total topoisomerase II activity.

MeSH Terms
Animals Blotting, Northern Blotting, Western Cell Division Cell Line Cell Nucleus/enzymology Cell Transformation, Neoplastic/metabolism DNA Damage DNA Topoisomerases, Type II/classification,metabolism Genes, ras Mice Molecular Weight Novobiocin/pharmacology RNA, Messenger/genetics Teniposide/pharmacology Thiobarbiturates/pharmacology Topoisomerase II Inhibitors
Chemicals
RNA, Messenger Thiobarbiturates Topoisomerase II Inhibitors Novobiocin Teniposide DNA Topoisomerases, Type II merbarone
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Woessner R D
Research & Development, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
Chung T D
Hofmann G A
Mattern M R
Mirabelli C K
Drake F H
Johnson R K
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
0008-5472
Published
1990-05-15
Pages
2901-8
Language
English
Region
United States
NLM ID
2984705R
Subset
IM
Grants
NCI NIH HHS · CA-40884 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]